Review



human pbk model  (Simcyp)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Simcyp human pbk model
    Overview of identified major uncertainties related to metabolism and excretion processes of the available <t> PBK model </t> for acetamiprid.
    Human Pbk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pbk+model/pmc11094581-1162-3-2?v=Simcyp
    Average 90 stars, based on 1 article reviews
    human pbk model - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites"

    Article Title: Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites

    Journal: EFSA Journal

    doi: 10.2903/j.efsa.2024.8759

    Overview of identified major uncertainties related to metabolism and excretion processes of the available PBK model for acetamiprid.
    Figure Legend Snippet: Overview of identified major uncertainties related to metabolism and excretion processes of the available PBK model for acetamiprid.

    Techniques Used: Radioactivity, Selection, In Vivo

    Schematic overview of interrelation of identified uncertainties related to metabolism and excretion processes of acetamiprid and IM‐2‐1 in the available PBK model for acetamiprid. The PBK model parameter values chosen for the kinetic processes related to U1, U2 and U4 impact on predicted internal and urinary acetamiprid concentrations (U6). The PBK model parameter values chosen for the kinetic processes related to U1–U5 impact on predicted internal and urinary IM‐2‐1 concentrations (U7).
    Figure Legend Snippet: Schematic overview of interrelation of identified uncertainties related to metabolism and excretion processes of acetamiprid and IM‐2‐1 in the available PBK model for acetamiprid. The PBK model parameter values chosen for the kinetic processes related to U1, U2 and U4 impact on predicted internal and urinary acetamiprid concentrations (U6). The PBK model parameter values chosen for the kinetic processes related to U1–U5 impact on predicted internal and urinary IM‐2‐1 concentrations (U7).

    Techniques Used:



    Similar Products

    human pbk model  (Simcyp)
    90
    Simcyp human pbk model
    Overview of identified major uncertainties related to metabolism and excretion processes of the available <t> PBK model </t> for acetamiprid.
    Human Pbk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pbk+model/pmc11094581-1162-3-2?v=Simcyp
    Average 90 stars, based on 1 article reviews
    human pbk model - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Overview of identified major uncertainties related to metabolism and excretion processes of the available PBK model for acetamiprid.

    Journal: EFSA Journal

    Article Title: Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites

    doi: 10.2903/j.efsa.2024.8759

    Figure Lengend Snippet: Overview of identified major uncertainties related to metabolism and excretion processes of the available PBK model for acetamiprid.

    Article Snippet: Although the Simcyp human PBK model was considered to be relevant, it could not be applied by the WG to answer assessment question 1b, since Simcyp Simulator software is a proprietary software that can only be used following a dedicated training.

    Techniques: Radioactivity, Selection, In Vivo

    Schematic overview of interrelation of identified uncertainties related to metabolism and excretion processes of acetamiprid and IM‐2‐1 in the available PBK model for acetamiprid. The PBK model parameter values chosen for the kinetic processes related to U1, U2 and U4 impact on predicted internal and urinary acetamiprid concentrations (U6). The PBK model parameter values chosen for the kinetic processes related to U1–U5 impact on predicted internal and urinary IM‐2‐1 concentrations (U7).

    Journal: EFSA Journal

    Article Title: Statement on the toxicological properties and maximum residue levels of acetamiprid and its metabolites

    doi: 10.2903/j.efsa.2024.8759

    Figure Lengend Snippet: Schematic overview of interrelation of identified uncertainties related to metabolism and excretion processes of acetamiprid and IM‐2‐1 in the available PBK model for acetamiprid. The PBK model parameter values chosen for the kinetic processes related to U1, U2 and U4 impact on predicted internal and urinary acetamiprid concentrations (U6). The PBK model parameter values chosen for the kinetic processes related to U1–U5 impact on predicted internal and urinary IM‐2‐1 concentrations (U7).

    Article Snippet: Although the Simcyp human PBK model was considered to be relevant, it could not be applied by the WG to answer assessment question 1b, since Simcyp Simulator software is a proprietary software that can only be used following a dedicated training.

    Techniques: